# Bristol Myers Squibb

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/bristol-myers-squibb
Canonical HTML page: https://gethealthbrief.com/entity/bristol-myers-squibb

## Timeline

- **2026-03-09**: DCAT Week 2026 — LOTTE Biologics engages in high-level partnership talks in New York City.
- **2025-12-01**: ADC Expansion — Completion of specialized ADC manufacturing lines at the Syracuse facility.
- **2024-03-15**: Songdo Groundbreaking — Construction begins on the first Mega Plant in Songdo, South Korea.
- **2023-01-01**: Syracuse Acquisition — LOTTE Biologics completes the acquisition of the Syracuse, NY plant from Bristol Myers Squibb.

## Recent coverage (6 stories)

### AstraZeneca-BMS £300bn Merger Could Reshape Global Drug Access and Pricing
2026-08-03 09:57:07 · Sentiment: Neutral · Impact: 9/10 · Sources: 4

The potential combination of two pharmaceutical powerhouses would concentrate ownership of critical cardiovascular and oncology treatments, raising concerns about pricing power, NHS supply chains, and worldwide health equity.
Full story: https://gethealthbrief.com/story/astrazeneca-bms-merger-healthcare-impact

### AZN-BMS $400B Talks: What It Means for Drug Prices and Access
2026-08-02 23:37:50 · Sentiment: Neutral · Impact: 9/10 · Sources: 2

A potential $400 billion merger between AstraZeneca and Bristol Myers Squibb could reshape oncology competition, with implications for drug costs, patient access, and payer negotiations. The combined portfolio would dominate key cancer markets.
Full story: https://gethealthbrief.com/story/astrazeneca-bms-merger-pricing-access

### Pfizer & Bristol Myers: 2 Dirt-Cheap Pharma Stocks Yielding 6%+ for Healthcare Investors
2026-07-08 21:22:01 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Pfizer and Bristol Myers Squibb combine high dividend yields with deep healthcare pipelines, offering a compelling income-entry into a sector facing patent cliffs but also rich in innovation. For healthcare investors, the stocks demand a long-term view on drug development amid evolving policy risks.
Full story: https://gethealthbrief.com/story/dirt-cheap-dividend-stocks-pfizer-bristol-myers-healthcare

### Nyxoah and Alumis Report Q4 Earnings Misses Amid Clinical Scaling Pressures
2026-03-20 01:55:23 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Both Nyxoah and Alumis reported quarterly earnings that missed analyst expectations by $0.04 per share, reflecting the high operational costs of late-stage clinical trials and pre-commercialization activities. Despite the financial shortfall, both companies remain on track with pivotal regulatory and clinical milestones in the sleep apnea and immunology sectors.
Full story: https://gethealthbrief.com/story/nyxoah-alumis-q4-earnings-miss-analysis

### Cognitive Decline Linked to Increased Need for Anticoagulant Therapy
2026-03-18 16:52:26 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

New research indicates that patients with Mild Cognitive Impairment (MCI) and dementia are at a significantly higher risk for developing cardiovascular conditions requiring anticoagulants. This finding underscores the clinical challenge of managing stroke prevention in cognitively impaired populations with high fall risks.
Full story: https://gethealthbrief.com/story/cognitive-decline-anticoagulant-risk

### LOTTE Biologics Targets Global Expansion at DCAT Week 2026
2026-03-09 07:39:53 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

LOTTE Biologics is attending DCAT Week 2026 in New York to secure high-value global partnerships and solidify its position in the CDMO market. This move underscores the company's aggressive strategy to leverage its U.S. manufacturing footprint and upcoming South Korean capacity.
Full story: https://gethealthbrief.com/story/lotte-biologics-dcat-week-2026-global-partnerships

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.